Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

CARMELINA: Linagliptin no effect on cognitive decline

Jackey Suen
26 Nov 2018
Prof Geert Jan Biessels

Linagliptin has no impact on cognitive decline when given on top of standard of care in patients with type 2 diabetes mellitus (T2DM), a CARMELINA substudy has shown.

“While the primary objective of the placebo-controlled CARMELINA study was to examine the long-term cardiovascular [CV] safety of linagliptin in patients with T2DM and comorbid CV and/or kidney diseases, it also explored the effect of linagliptin on cognitive decline,” explained investigator Professor Geert Jan Biessels of the University Medical Center Utrecht, the Netherlands.

In this substudy, however, the incidence of accelerated cognitive decline was comparable between the linagliptin and placebo groups (28.4 percent vs 29.3 percent; risk ratio, 0.96; p=0.6938).

The substudy included 1,545 CARMELINA participants (linagliptin, n=800; placebo, n=745). The primary endpoint of incidence of accelerated cognitive decline was defined as Mini Mental State Examination (MMSE) and/or attention and executive functioning score ≤16th percentile of the regression-based index scores for cognitive decline in the total study population. Baseline and end-of-treatment cognitive assessments were conducted around 2.5 years apart.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.